Barclays
IMPL

Barclays’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Barclays’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,039
Closed -$7K – 5368
2022
Q1 		$7K Buy
+1,039
New +$7.85K ﹤0.01% 4660

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Barclays's IMPL Position: Q2 2022 in Review

Barclays sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q2 2022, closing a stake of 1,039 shares — an estimated $7K sold.

Barclays first reported a position in IMPL in Q1 2022 and held it in 1 quarter. The position peaked at $7K in Q1 2022. 36 funds tracked by Wall St. Rank hold IMPL as of Q2 2022.

  • Barclays reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 1,039 Impel Pharmaceuticals Inc. Common Stock shares in Q2 2022, an estimated $7K.
  • Barclays first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Barclays's Impel Pharmaceuticals Inc. Common Stock position peaked at $7K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.